Navigation Links
Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease

which one condition can lead to the exacerbation of the other and, ultimately, to death. In particular, renal anemia, diabetes and cardiovascular disease frequently play this double role.

About MIRCERA

The initial registration clinical program for MIRCERA consisted of 10 global studies involving more than 2,700 patients from 29 countries. The Phase III program for MIRCERA consisted of two correction and four maintenance studies exploring intravenous and subcutaneous MIRCERA at extended administration intervals.

Roche filed applications with the regulatory authorities in the United States and in the European Union in April 2006 seeking approval for the use in the treatment of anemia associated with CKD in patients on dialysis and not on dialysis.

Safety Information

MIRCERA has a demonstrated safety profile comparable to other erythropoietic agents.

The most commonly reported adverse events in the MIRCERA Phase II/III clinical program were hypertension, nasopharyngitis and diarrhea. Erythropoietic therapies increase the risk of death and serious cardiovascular events when administered to a hemoglobin of greater than 12 g/dL.

Erythropoiesis stimulating agents, when administered to target a hemoglobin of greater than 12 g/dL have shortened the time to tumor progression, shortened survival and increased the risk of death in cancer patients.

Pure Red Cell Aplasia (PRCA) has been observed in patients treated with erythropoietin therapy. However, PRCA has not been observed with MIRCERA in clinical trials to date.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years, the Roche Group has been committed to developing innovative products and services that address prevention, diagnosis and treat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
5. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
6. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
(Date:5/8/2008)...AVEN, Conn., May 8 /- VION ...nced the start of an investigator-sponsored,Phase ...loretazine(R),(VNP40101M) in combination with cyta...ed acute myelogenous leukemia (AML) and high-risk,...g conducted under the,direction of Ellen K. Ritchi...
(Date:5/8/2008)...ial Sloan-Kettering Cancer Center Investigators to... Ovarian Cancer Patients -, BRISBANE, Calif., May...unced the expansion of Phase 2 clinical trial prog...cer. This is the third major clinical trial,of BSI... expanding on,on-going trials in breast and brain ...
(Date:5/8/2008)...ON, May 8 /- Go Healthy (Pi...er clinical trials with Cholesterade (R),in three ... group of 200,patients in 6 centers around the cou...titute at The Methodist Hospital in the Texas Medi... Bryan was formerly the Team,Physician for the Hou...
(Date:5/7/2008)...IEGO, May 7 /- Arena Pharma...hat Taisho Pharmaceutical Co., Ltd.,initiated a Ph...PCR-focused,partnership with Arena to develop comp...didate is a novel oral compound intended for the t...re very happy to see our long-standing partner, Ta...
Breaking Medicine Technology:Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3NutraCea Files Universal Shelf Registration Statement 10451 1NutraCea Files Universal Shelf Registration Statement 10451 2Candidates Risk Harming Voice in Final Week to Super Tuesday 10448 1Candidates Risk Harming Voice in Final Week to Super Tuesday 10448 2GfK Asia Provides New View on the Optics Industry 10445 1GfK Asia Provides New View on the Optics Industry 10445 2GfK Asia Provides New View on the Optics Industry 10445 3Deep brain stimulation may improve memory 10442 1Deep brain stimulation may improve memory 10442 2
...- Gemin X Biotechnologies,Inc. announced today tha...ated that its lead compound, obatoclax (GX15-070),...ma (MCL) cell lines and,primary cells from 11 MCL ... specifically designed to inhibit all relevant mem...er target, thus restoring,the natural cell death p...
...al data on leading,drug-eluting stent portfolio, N...-- Boston,Scientific Corporation today announced t...s announcements at the annual Paris,Course on Reva...22,to 25 in Barcelona, Spain. , "We will be announ...and registries, adding to the knowledge base for t...
Other Medicine Technology:Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3Boston Scientific Announces Schedule for EuroPcr 2007 2Boston Scientific Announces Schedule for EuroPcr 2007 3Boston Scientific Announces Schedule for EuroPcr 2007 4Boston Scientific Announces Schedule for EuroPcr 2007 5
(Date:5/9/2008)...ire/ -- OxyBand Technologies, Inc. today,announced...tes Army to,evaluate the company,s patented cuttin...d other military wounds. OxyBand Technologies has ...rs pure oxygen gas into wounds for,faster healing....rials to,accelerate healing and, in laboratory tes...
(Date:5/9/2008)... Supply Flights en Route, NEW YORK, May 9 /PRNews...UNICEF emergency supplies landed in Yangon today, ... Three more planeloads containing,medicines, emerg...,children, are planned over the next three days., ...second can make a,difference in the life of a Myan...
(Date:5/9/2008)...fixture of European nightlife, study says , ... and young adults in Europe are drinking alcohol a...a survey of more than 1,300 people who are regular...third of males and a quarter of females aged 16 to..., while cocaine, ecstasy and cannabis are used to ...
(Date:5/9/2008)...d by the artery-opening devices , , FRID... cornerstone of heart-disease treatment, tiny tool...ents by maintaining the flow of blood through thei...nserted following artery-clearing angioplasty proc...tant supply of blood to the heart and throughout t...
Breaking Medicine News(10 mins):Health News:OxyBand Technologies Signs Army Contract 2Health News:UNICEF: 'Every Second Can Make a Difference' to Myanmar's Children; 20% Already Suffering from Diarrhea, Malaria reported 2Health News:UNICEF: 'Every Second Can Make a Difference' to Myanmar's Children; 20% Already Suffering from Diarrhea, Malaria reported 3Health News:Young Adults Using Alcohol, Drugs for Better Sex 2Health News:Drug-Coated Stents Still Spark Debate 2Health News:Drug-Coated Stents Still Spark Debate 3
...quent ventricular ectopy, another name for prematu...been found by researchers to be a better predictor... during exercise. Doctors from Cleveland Clinic Fo...y of heart failure, valve disease or arrhythmia. T...
...amin C has been believed, over the years, to be a ... has now been proved to be true by researchers who... vitamin C. The researchers reported that in their...f vitamin C a day for two weeks, they found a boos...
... New Scientist magazine in its January issue has r...burgers, fries and foods high in fat and calories ...eating oneself to obesity is not just due to a lac... hormonal changes caused by the fast foods, in the...
...hn's disease is an often debilitating, lifelong ga...people are in their 20s or 30s. The disease leaves... or it causes severe abdominal pain. However, trea...ts suffering from the disease. Now, Dr. Brian Diec...
Other Medicine News:
Increased volume for use with 4, 8, or 12 channel pipettors. Angled sides and V-shaped bottom permits withdrawal of nearly all of the solution. Corners have pouring lips to dispose of excess solution
Volume: 2 ml; Volume Graduation: 1/100 ml
... use with measuring pipettes, enables you to pipet.... It works with all types of glass or plastic pipe...ns Pipette Aid is equipped with a safety valve and...echanism of the device from contamination by the v...
The Finnpipette BioMate pipetting aid excels when it comes to precise pipetting. The aspirate/dispense speed can be easily selected using the speed-setting slide switch. The powerful pump quickly fil
Medicine Products: